课题基金 / 基金详情

项目摘要

项目成果

WILLIAM A. GARLAND的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Inhibitor of differentiation (Id) genes and proteins play a significant role in tumor biology, and an anti-Id therapy in combination with a taxanes, a widely prescribed class of cytotoxic (paclitaxel/docetaxel, docetaxel or protein-bound paclitaxel) to treat cancer, is hypothesized to significantly improve the efficacy of the taxane without compromising safety while also providing additional anti-cancer activity. An effective Id1 inhibitor would potentially improve the efficacy of the taxanes by three distinct mechanisms: (i) preventing endothelial repair and thereby promoting the intrinsic anti-angiogenic effect of paclitaxel/docetaxel, (ii) lowering the anti-apoptotic environment of the tumor making it more susceptible to the cytotoxicity of paclitaxel/docetaxel and (iii) augmenting the cytotoxicity of paclitaxel/docetaxel by a direct anti-cancer effect. The goal of this proposal is to provide data to justify formal preclinical development and initial clinical evaluation of this therapeutic approach with an anti-Id1 small molecule. Experiments to be funded by the grant include xenograft studies in mice to establish the optimum dosing regimen for both the anti-Id agent and the taxanes. PUBLIC HEALTH RELEVANCE: Anti-microtubule taxanes like paclitaxel and docetaxel are widely prescribed cytotoxics to treat cancer. An effective Id1 inhibitor would potentially improve the efficacy of taxanes by three distinct mechanisms: (i) preventing endothelial repair and thereby promoting the intrinsic anti-angiogenic effect of taxanes, (ii) lowering the anti-apoptotic environment of the tumor making it more susceptible to the cytotoxicity of the taxanes, and (iii) augmenting the cytotoxicity of the taxanes by a direct anti-cancer effect. The goal of this proposal is to provide data to justify formal preclinical development and initial clinical evaluation of this therapeutic approach using an anti-Id1 small molecule.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Suppressors of kRAS Activity Discovered Using a Fruit Fly-based In-vivo Screen
  • 批准号:
    9335553
  • 项目类别:
  • 资助金额:
    $104.37万
  • 财政年份:
    2014
  • 负责人:
    WILLIAM A. GARLAND
  • 依托单位:
Screening with D. melanogaster to Discover Inhibitors G12V Mutated kRAS
  • 批准号:
    8781928
  • 项目类别:
  • 资助金额:
    $22.5万
  • 财政年份:
    2014
  • 负责人:
    WILLIAM A. GARLAND
  • 依托单位:
Anchored Antioxidants to Provide Increased Protective Effect
  • 批准号:
    7926453
  • 项目类别:
  • 资助金额:
    $19.95万
  • 财政年份:
    2010
  • 负责人:
    WILLIAM A. GARLAND
  • 依托单位:
NRTS AS THERAPEUTICS FOR DEMENTIA ASSOCIATED WITH HIV
  • 批准号:
    2714277
  • 项目类别:
  • 资助金额:
    $35.52万
  • 财政年份:
    1996
  • 负责人:
    WILLIAM A. GARLAND
  • 依托单位:
海外基金